The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors

The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies

(2022) Mika L Persson et al.   NEURO-ONCOLOGY

Clinical Intervention Using Focused Ultrasound (FUS) Stimulation of the Brain in Diverse Neurological Disorders

(2022) Hongchae Baek et al.   Frontiers in Neurology

Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma

(2022) Casper J. Pachocki et al.   Journal of Neuroinflammation

Research progress in inducing immunogenic cell death of tumor cells

(2022) Deqian Xie et al.   Frontiers in Immunology

Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation

(2020) Shuang Qin et al.   Frontiers in Oncology

IMMU-09. OUTCOME OF PATIENTS WITH RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TREATED WITH PEMBROLIZUMAB (ANTI-PD-1): A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC045)

(2018) Eugene Hwang et al.   NEURO-ONCOLOGY